• Retagliptin Phosphate Tablets approved by China NMPA for type 2 diabetes

    Information 2023-07-26

    Jun,2023. Retagliptin Phosphate Tablets, the Class 1. New drug from Jiangsu Hengrui Pharmaceuticals Co., Ltd for the treatment of type 2 diabetes, is approved by China NMPA. Retagliptin phosphate is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor that inhibits DPP-4 to hydrolyze the incretin hormone, thereby increasing the plasma concentration of active glucagon-like peptide-1 (GLP-1) and glucose dependent insulin-like polypeptide (GIP). It increases the release of insulin in a glucose dependent manner and decreases glucagon to reduce…

    Read More »
  • Centralized medical procurement saves patients more money

    Information 2023-04-06

    The eighth and latest round of the government’s centralized medical procurement has resulted in an average price cut of 56 percent for 39 types of medicines, including the antiviral drug Oseltamivir and popular blood pressure therapies, the National Healthcare Security Administration said on Wednesday evening. The price reduction is expected to save 16.7 billion yuan ($2.4 billion) annually, it added. The bidding result released on Wednesday is preliminary and a final version will be published in the near future. This…

    Read More »
  • Biosimilar Tocilizumab Injection approved for marketing

    Information 2023-02-01

    Recently, the Tocilizumab Injection (Chinese trade name:施瑞立) of Bio-Thera Solutions, Ltd. is approved for marketing by China NMPA. This drug is the first Tocilizumab Injection biosimilar approved in China, which is indicated for rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome. Tocilizumab is a recombinant humanized monoclonal antibody against the human interleukin-6 (IL-6) receptor that specifically binds to soluble and membrane-bound IL-6 receptors and inhibits signal transduction mediated by IL-6 receptors. At present, the Tocilizumab Injection has been…

    Read More »
  • How to choose children’s cosmetics scientifically

    Information 2022-12-13

    Children’s cosmetics refer to cosmetics for children aged 12 and younger. How to choose children’s cosmetics scientifically is a matter of great concern to parents. Parents can choose appropriate products in accordance with the needs of children of different ages. Sunscreen: For newborns, there is less demand for outdoor activities. Infants under the age of six months have delicate skin and a high ratio of body surface area to body weight. Applying sunscreen is more likely to have adverse reactions….

    Read More »
  • FDA grants EUA to Lilly’s bebtelovimab for Covid-19 treatment

    Information 2022-03-01

    The US Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) to Eli Lilly and Company’s bebtelovimab to treat mild-to-moderate Covid-19. Bebtelovimab is a neutralising IgG1 monoclonal antibody that is directed against the SARS-CoV-2 virus’ spike protein. Under the FDA EUA, the antibody is indicated to treat mild-to-moderate Covid-19 in adults and paediatric patients aged 12 years and above. It is intended for patients at an increased risk of disease progression, including hospital admission or mortality, and…

    Read More »
  • 4 Chinese COVID-19 vaccines undergoing phase-3 clinical trials

    Information 2020-09-03

    4 Chinese COVID-19 vaccine candidates have started international phase-3 clinical trials, according to the State Council joint prevention and control mechanism against COVID-19. Some of the phase-3 trials are expected to complete the first round of vaccinations in early September, with preliminary data expected as early as November. Phase-3 clinical trials usually involve thousands of people to verify the safety and effectiveness of the vaccines, which are key to their market approval. As the epidemic has been brought under control…

    Read More »
  • China Develops novel rabies vaccine

    Information 2020-07-01

    A novel rabies vaccine for humans shows promise in preclinical testing, according to a new study published in the journal EBioMedicine. This live, attenuated vaccine candidate was developed and tested by scientists at the Wuhan Institute of Virology under the Chinese Academy of Sciences and Wuhan-based Huazhong Agricultural University. The research team constructed a novel chimeric virus, VEEV-RABV-G, through replacing the entire structural proteins of the Venezuelan equine encephalitis virus (VEEV) with the rabies virus glycoprotein (RABV-G), as the single…

    Read More »